Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Yasir Y Elamin, MD
CONTACT
Lead
M.D. Anderson Cancer Center
Primary Objective: 1\. To compare the PFS of ALK+ NSCLC patients treated with lorlatinib to those treated with lorlatinib and local consolidation therapy (LCT) Secondary Objectives: 1. To assess the safety and tolerability of lorlatinib and LCT. 2. To increase trial enrollment in underserved population 3. To determine overall survival (OS) in patients treated with single agent lorlatinib vs lorlatinib plus LCT. 4. To assess the time to progression of non-LCT lesions in the lorlatinib plus LCT arm. Exploratory Biomarkers Objectives: 1. To determine the utility of pre-treatment, pre-LCT, and post-LCT circulating free tumor DNA (cfDNA) as potential prognostic and predictive biomarkers. 2. To evaluate potential impact of LCT on mechanisms of lorlatinib resistance with molecular analysis of postprogression biopsies.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted